Due to the susceptibility of BCL-2 inhibition in IDH-mutant AML patients mentioned previously, the combination of IDH inhibitors with venetoclax, a BCL-2 inhibitor, is being explored. The gene discussed is IDH1; the disease is acute myeloid leukemia.